Technically you are right. But the Q will show any sales made. Legally, from what has been explained to me, it would be fine to 8k a sale, for instance If Blink was sold, if there was no intention to buy the stock back.
I can only explain what I did, and that was to continue to buy warrants because of the strange inverse Arb and then exercise the warrants. As a result I exercised over 500k warrants which went into the Company’s till.
I don’t know how Taug treated the upward move but clearly buying the warrants were a great deal. At one point warrants were 35percent less than the strike price. The process of exercising warrants was simple but I am still waiting for some settlement.
As far as VTGN if the price spikes and stays higher by the end of the quarter shareholders will have a better snapshot of what is being held and what the value is. Obviously the day after the quarter ends prices and positions can change.
In any event, the Q reflects the recent upward moves in all the positions.
With UBS and Oppenheimer now covering VTGN and valuing it today at 6 is a positive. UBS even goes so far as to mention other analysts are $20 and higher, assuming phase 2 data is good.
Taug interest in AYTU is very interesting to, I do not like small pharmaceuticals biotech’s launching a product on their own. But in this case the timing may be great as the stock was beaten down to a very low valuation. This is a very good testosterone drug, in fact it could end up being best in class and I can see scripts doubling quarter over quarter and when they get a powerful sales force or hopefully joint venture this sales could EXPLODE. Is that to hypey.
News 
Market Data 
Discover 
